Imaging Agent

DRUG3 trials

Sponsors

City of Hope Medical Center, NRG Oncology, Vanderbilt-Ingram Cancer Center

Conditions

Buccal Mucosa Squamous Cell CarcinomaFloor of Mouth Squamous Cell CarcinomaGingival Squamous Cell CarcinomaHard Palate Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaLip Squamous Cell CarcinomaLower Alveolar Ridge Squamous Cell CarcinomaOral Cavity Squamous Cell Carcinoma

Phase 1

Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma

CompletedNCT03311828

City of Hope Medical CenterPlasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Secondary Amyloidosis

Start: 2018-02-21End: 2023-06-05Updated: 2024-03-12

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

RecruitingNCT05901545

Vanderbilt-Ingram Cancer CenterHead and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

Start: 2023-08-22End: 2029-11-30Target: 30Updated: 2026-03-05

Phase 2

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

RecruitingNCT04333537

NRG OncologyBuccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma +9

Start: 2020-09-23End: 2031-04-27Target: 686Updated: 2026-04-03

Related Papers

NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.

Journal of Clinical Oncology2021-05-2011 citations

Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab

Blood Advances2020-10-2342 citations